Company Information

  

Address: 4B CEDAR BROOK DRIVE  
City: CRANBURY 
State: NJ 
Zip Code: 08512 
Telephone: 609-495-2200 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our most advanced product candidate is Vyleesi(TM), the trade name for bremelanotide, a peptide melanocortin receptor 4 (MC4r) agonist, for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder ("HSDD"), which is a type of female sexual dysfunction ("FSD"), defined as low desire with associated distress or interpersonal difficulty. A New Drug Application ("NDA") has been submitted to the U.S. Food and Drug Administration ("FDA") by our exclusive North American licensee, AMAG Pharmaceuticals, Inc.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/20180.12NA8.08
03/20180.02NA54.50
12/20170.13NA6.61
09/20170.06NA11.05
06/2017-0.07NAN/E
03/2017-0.23NAN/E
12/2016-0.30NAN/E
09/2016-0.33NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2018 Leverage 2018
Net Inc/Comm Equity0.07Total Liab/Total Assets0.31
Net Inc/Total Assets0.63Total Liab/Inv Cap0.54
Net Inc/Inv Cap1.11Total Liab/Comm Equity0.03
Pretax Inc/Net Sales0.37Interest Coverage Ratio18.07
Net Inc/Net Sales0.37Curr Debt/Equity0.22
Cash Flow/Net Sales0.03LTD/Equity0.01
SG&A/NetSales0.13Total Debt/Equity0.23
Asset Utilization   Liquidity  
Net Receivables Turnover8.88Quick Ratio3.58
Inventory TurnoverNACurrent Ratio3.58
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap2.42Inv/Curr AssetsNA
Net Sales/PP&E409.27  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 20.62 8.96 10.61 26.94
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.06 2.41 1.63 1.54
Operating Income 12.27 -0.52 2.94 11.23
Interest Exp 0.28 0.33 0.39 0.46
Pretax Income 12.08 -0.76 2.63 10.83
Other Income 0.09 0.09 0.08 0.05
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 11.81 -0.74 3.03 10.60

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 38.00 25.74 34.96 39.96
Receivables - Total 0.00 0.00 0.00 9.39
Inventories - Total NA NA NA NA
Total Current Assets 38.51 26.44 36.25 50.29
Net Property, Plant & Equipment 0.16 0.17 0.18 0.19
Total Assets 39.02 27.16 36.98 50.54
Liabilities        
Accounts Payable 4.33 6.69 6.23 11.42
Debt in Current Liabilities 5.95 6.92 7.89 7.86
Total Current Liabilities 10.76 14.20 23.67 39.44
Long-Term Debt 0.33 1.33 2.32 4.31
Total Liabilities 12.05 16.93 27.36 44.56
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 2.01 1.95 1.95 1.84
Retained Earnings -332.05 -343.85 -343.11 -346.14
Treasury Stock NA NA NA NA
Total Stockholders' Equity 26.96 10.23 9.63 5.98
Total Liabilities and Stockholders' Equity 39.02 27.16 36.98 50.54

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities 10.49 -7.23 -2.99 1.43
Net Cash Provided by Investing Activities -0.01 0.00 0.25 -0.01
Net Cash Provided by Financing Activities 1.78 -1.99 -2.01 -1.92

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20140.00-13.93-0.13
06/201512.95-17.67-0.15
06/20160.00-51.71-0.33
06/201744.72-13.33-0.07
06/201867.1324.700.12
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1810241,72820.65




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.